REMARKS

Entry of the foregoing and reexamination and reconsideration of the subject application, as amended, pursuant to and consistent with 37 C.F.R. §1.112, are respectfully requested in light of the remarks which follow.

Claims 1-11, 13, 14, 16, 17, 21, 24, 25, 27-29 and 32-42 remain in the application.

Claim 14 has been corrected above to change its dependency from Claim 12 to Claim 13. As amended, Claim 14 no longer depends from a cancelled claim.

Claim 24 has been amended to correct a misspelling.

Claim 28 has been amended to remove extraneous language.

In response to the election of species requirements, applicants hereby elect, with traverse, α -hydroxy acid as the additional ingredient of species (a), xerosis as the disease of species (b) and aspartylglucosaminidase AGA as the compound of species (c).

With respect to α -hydroxy acid species (a), all of Claims 1-11, 13, 14, 16, 17, 21, 24, 25, 27-29 and 32-42 read on the elected species.

With respect to xerosis species (b), at least Claims 1-11, 13, 14, 16, 17, 21, 24, 27, 33 and 35-39 read on the elected species.

With respect to aspartylglucosaminidase AGA species (c), all of Claims 1-11, 13, 14, 16, 17, 21, 24, 25, 27-29 and 32-42 read on the elected species.

Attorney's Docket No. <u>1016800-000583</u> Application No. <u>10/757,505</u> Page 12

Nevertheless, the election of species requirements are traversed because election of species normally presupposes that no generic claim is allowable and no art has been adduced which would militate against the allowance of a generic claim herein. Reconsideration and withdrawal of the restriction requirement are respectfully requested.

Respectfully submitted,

BUCHANAN INGERSOLL PC

Date: February 24, 2006

Mary Katherine Baumeiste Registration No. 26,254

P.O. Box 1404 Alexandria, Virginia 22313-1404 (703) 836-6620